US-based pharmaceuticals company Alvogen, Inc. announced on Friday that it is recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level.
The recalled lot is Lot 108319 25 mcg/h with expiration date April 2027.
Alvogen is recalling the product as the patches could potentially be multi-stacked, adhered one on top of the other, in a single product pouch. There is a possibility that the application of a multi-stacked 25 mcg/h patch could result in serious, life threatening, or fatal respiratory depression. The firm has received one serious adverse event related to this recall to date.
Kindeva Drug Delivery LP, Northridge, California manufactures the transdermal system, which is distributed by Alvogen, Inc. as a private label distributor.
OS Therapies secures US patent for OST-HER2 manufacturing, extending exclusivity to 2040
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
Kexing Biopharm's GB05 IND application receives US FDA approval
AroCell secures Chinese patent for respiratory infection detection
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
Health Canada approves Merck's KEYTRUDA for resectable non-small cell lung cancer
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline
Henlius's serplulimab approved in Europe for Extensive-Stage Small Cell Lung Cancer
Polarean Imaging expands reach with Taiwanese distribution deal
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
hVIVO to conduct RSV human challenge trial for Inhalon Biopharma